RDY
DR REDDYS LABORATORIES LTD
$13.37
+1.06%
$11.0B
No data for this timeframe.
Vol
Market Cap$11.0B
Cap SizeLarge Cap
Inst. Holders6 funds
Inst. Value$320.1M
Inst. Activity1 buys / 1 sells
SEC Reports20
Recent Activity
Jun 5, 2026
SEC
Dr. Reddy's filed a routine 6-K reporting the allotment of 12,100 equity shares upon exercise of stock options under exi
6-K — Impact 2/10
Jun 3, 2026
SEC
Dr. Reddy's filed a Form 6-K on June 3, 2026, disclosing that management will participate in two investor conferences: a
6-K — Impact 2/10
Jun 3, 2026
short_volume
Short Volume: RDY — 62.1% short (0.3M / 0.5M)
Short: 325,528 | Exempt: 0 | TRF Vol: 524,162 | Short Ratio: 62.1% | Off-exchange volume (dark pool
Jun 1, 2026
SEC
Dr. Reddy's filed a routine 6-K furnishing a notice of upcoming investor meetings with Bank of America on June 5, 2026.
6-K — Impact 2/10
Inst.
MORGAN STANLEY — ADD
8,926,051 shares ($125.3M)
Inst.
CAUSEWAY CAPITAL MANAGEMENT LLC — EXIT
0 shares ($0.00)
Jun 1, 2026
Event
Valganciclovir
WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENES
Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$14.20 (Jun 2025)
Current $13.37
Low $11.44
Median $13.99
High $16.77
5 analysts
$11.44
$16.77
Analyst Ratings
8Strong Buy
15Buy
10Hold
7Sell
4Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2025 | HSBC | UPGRADE | Hold → Buy |
| Nov 6, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| Jul 30, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| May 8, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
| Jan 29, 2024 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $51.04 | $51.04 — $51.04 | -8% YoY | 1 |
| Next FY | $63.32 | $63.32 — $63.32 | 24% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $125.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $115.9M | DOUBLED |
| VANGUARD GROUP INC | $70.6M | — |
| BANK OF AMERICA CORP | $7.0M | TRIM |
| FMR LLC | $1.2M | — |
6 institutional holders with $320.1M total value (22,801,556 shares) as of 2025-Q4. Top holders: MORGAN, RENAISSANCE, VANGUARD.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8,926,051 | $125.3M | 39.1% | ADD +41.2% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 8,255,128 | $115.9M | 36.2% | DOUBLED +382.9% |
| 3 | VANGUARD GROUP INC | 5,027,272 | $70.6M | 22.0% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 496,925 | $7.0M | 2.2% | TRIM -53.1% |
| 5 | FMR LLC | 86,742 | $1.2M | 0.4% | — |
| 6 | WELLS FARGO & COMPANY/MN | 9,438 | $132.5K | 0.0% | DOUBLED +495.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 6,322,154 | 8,926,051 | +41.2% | $125.3M | 2025-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | EXIT | 159,139 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 4,854,849 | 6,322,154 | +30.2% | $88.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 869,889 | 408,041 | -53.1% | $5.7M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 8,736,296 | 4,854,849 | -44.4% | $73.0M | 2025-Q2 |
| UBS Group AG | ADD | 899,809 | 1,206,843 | +34.1% | $18.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,976,362 | 869,889 | -56.0% | $13.1M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 17,500 | 162,463 | +828.4% | $2.1M | 2025-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | TRIM | 539,305 | 144,439 | -73.2% | $1.9M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,242,132 | 11,258,915 | +402.2% | $177.8M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,950,449 | 9,418,428 | +382.9% | $148.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 17,217 | 780,822 | +4435.2% | $12.3M | 2024-Q4 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | DOUBLED | 107,861 | 539,305 | +400.0% | $8.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 9,500 | 17,500 | +84.2% | $276.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,314 | 7,826 | +495.6% | $123.6K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
20 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 18 neutral. Avg impact: 2.6/10.
NEUTRAL
6-K
2/10
Dr. Reddy's filed a routine 6-K reporting the allotment of 12,100 equity shares upon exercise of sto
Jun 5, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a Form 6-K on June 3, 2026, disclosing that management will participate in two inv
Jun 3, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a routine 6-K furnishing a notice of upcoming investor meetings with Bank of Ameri
Jun 1, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a Form 6-K on May 30, 2026, solely to announce that its annual Form 20-F for the f
Jun 1, 2026
NEUTRAL
20-F
2/10
Dr. Reddy's filed its annual Form 20-F for the fiscal year ended March 31, 2026, a routine annual re
May 29, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed its annual Secretarial Compliance Report for FY ended March 31, 2026, certifying c
May 28, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a 6-K announcing it will ring the NYSE Closing Bell on May 29, 2026 to celebrate 2
May 28, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's submitted a 6-K filing enclosing the transcript of its Q4 FY2026 earnings call held on M
May 18, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investo
May 18, 2026
BULLISH
6-K
6/10
Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health C
May 15, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories filed its Q4 FY26 audited financial results presentation via a 6-K on May 1
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories filed a 6-K providing a link to the audio recording of its Q4 FY2026 earnin
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's filed a routine 6-K reporting board meeting outcomes: re-appointment of an independent d
May 12, 2026
NEUTRAL
6-K
1/10
Dr. Reddy's management will participate in investor conferences hosted by HSBC (Mumbai, May 14-15) a
May 12, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock option
May 11, 2026
BULLISH
6-K
6/10
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, the first generic
Apr 29, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories announced it will release its Q4 and full year FY26 results on May 12, 2026
Apr 24, 2026
NEUTRAL
6-K
4/10
Dr. Reddy's Laboratories confirmed it has not yet received Health Canada approval for its Semaglutid
Apr 24, 2026
NEUTRAL
6-K
2/10
Dr. Reddy's Laboratories announced that its Board of Directors will consider recommending a final di
Apr 16, 2026
NEUTRAL
6-K
3/10
Dr. Reddy's Laboratories announced the sale of its wholly owned subsidiary, Svaas Wellness Limited,
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jun 2025): 52% buy across 44 analysts — 8 strong buy, 15 buy, 10 hold, 7 sell, 4 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$14.20 mean target (Jun 2025)
$11.44 Low
$16.77 High
| Metric | Value |
|---|---|
| Current Price | $13.37 |
| Target Low | $11.44 |
| Target Mean | $14.20 |
| Target Median | $13.99 |
| Target High | $16.77 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $80.9B | -5.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $88.1B | 0.0% | — |
| Current FY 2027-03-31 |
$51.04 | $51.04 | $51.04 | -7.8% | — | 0↑ 1↓ | $357.0B | 6.3% | 1 |
| Next FY 2028-03-31 |
$63.32 | $63.32 | $63.32 | 24.1% | — | 0↑ 1↓ | $393.8B | 10.3% | 1 |
11 analyst firms have rated this stock: 8 upgrades, 8 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2025 | HSBC | UPGRADE | Hold | Buy |
| Nov 6, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jul 30, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| May 8, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 29, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Jun 1, 2023 | Barclays | MAINTAIN | Overweight | Overweight |
| Oct 31, 2022 | Barclays | MAINTAIN | — | Overweight |
| Oct 25, 2022 | Barclays | MAINTAIN | — | Overweight |
| Sep 12, 2022 | Barclays | MAINTAIN | — | Overweight |
| Jul 25, 2022 | Barclays | MAINTAIN | — | Overweight |
| May 24, 2022 | Barclays | MAINTAIN | — | Overweight |
| Nov 1, 2021 | Barclays | MAINTAIN | — | Overweight |
| Feb 2, 2021 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Jan 28, 2020 | CLSA | DOWNGRADE | Buy | Outperform |
| Jan 9, 2020 | Citigroup | UPGRADE | Sell | Buy |
| Nov 4, 2019 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Sep 4, 2019 | Credit Suisse | UPGRADE | Underperform | Outperform |
| Jun 11, 2019 | Barclays | INITIATE | — | Equal-Weight |
| May 20, 2019 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Nov 1, 2017 | Jefferies | MAINTAIN | — | Underperform |
| Sep 21, 2017 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Jul 27, 2016 | HSBC | DOWNGRADE | Hold | Reduce |
| Jul 27, 2016 | Jefferies | DOWNGRADE | Hold | Underperform |
| Jul 26, 2016 | Credit Suisse | DOWNGRADE | Neutral | Underweight |
| May 2, 2016 | Goldman Sachs | INITIATE | — | Neutral |
| Feb 10, 2016 | CLSA | UPGRADE | Underperform | Buy |
| Dec 2, 2015 | Deutsche Bank | INITIATE | — | Sell |
| Feb 15, 2013 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Dec 12, 2012 | Credit Suisse | UPGRADE | Neutral | Outperform |
| Jun 28, 2012 | Anand Rathi | UPGRADE | Hold | Buy |
| Feb 7, 2012 | Credit Suisse | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 15 | 10 | 7 | 4 | 52% | |
| May 1, 2026 | 8 | 14 | 10 | 8 | 4 | 50% | |
| Apr 1, 2026 | 9 | 14 | 11 | 7 | 4 | 51% | |
| Mar 1, 2026 | 9 | 13 | 11 | 7 | 4 | 50% | |
| Feb 1, 2026 | 9 | 13 | 11 | 7 | 4 | 50% | |
| Jan 1, 2026 | 5 | 8 | 14 | 11 | 7 | 29% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: RDY — 62.1% short (0.3M / 0.5M)
Short: 325,528 | Exempt: 0 | TRF Vol: 524,162 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
Clinical Trial
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Phase Phase 3 — TERMINATED
Jun 2, 2026
Clinical Trial
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Phase Phase 2 — COMPLETED
Jun 2, 2026
short_volume
Short Volume: RDY — 59.3% short (0.4M / 0.6M)
Short: 385,126 | Exempt: 11 | TRF Vol: 649,826 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
FDA
Valganciclovir
WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FE
May 27, 2026
short_volume
Short Volume: RDY — 67.7% short (0.4M / 0.5M)
Short: 362,577 | Exempt: 0 | TRF Vol: 535,658 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase Phase 2 — TERMINATED
May 19, 2026
Clinical Trial
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Phase Phase 2 — COMPLETED
May 19, 2026
short_volume
Short Volume: RDY — 62.2% short (0.4M / 0.6M)
Short: 367,709 | Exempt: 0 | TRF Vol: 591,596 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
Clinical Trial
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase Phase 2 — TERMINATED
May 14, 2026
short_volume
Short Volume: RDY — 60.6% short (0.8M / 1.4M)
Short: 837,351 | Exempt: 618 | TRF Vol: 1,382,649 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: RDY — 72.2% short (1.3M / 1.8M)
Short: 1,317,650 | Exempt: 5,360 | TRF Vol: 1,824,458 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: RDY — 347,872 shares ($4.3M) failed to deliver
Settlement: 20260513, Price: $12.46, FTD Value: $4,334,485.12, DR. REDDY'S LABORATORIES ADS
May 12, 2026
short_volume
Short Volume: RDY — 88.1% short (1.8M / 2.0M)
Short: 1,761,799 | Exempt: 0 | TRF Vol: 1,999,198 | Short Ratio: 88.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: RDY — 86.8% short (1.2M / 1.4M)
Short: 1,186,296 | Exempt: 0 | TRF Vol: 1,366,112 | Short Ratio: 86.8% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: RDY — 88.9% short (0.8M / 0.9M)
Short: 773,129 | Exempt: 0 | TRF Vol: 869,234 | Short Ratio: 88.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: RDY — 90.7% short (1.0M / 1.1M)
Short: 952,506 | Exempt: 171 | TRF Vol: 1,050,586 | Short Ratio: 90.7% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: RDY — 90.3% short (1.6M / 1.7M)
Short: 1,558,423 | Exempt: 0 | TRF Vol: 1,725,677 | Short Ratio: 90.3% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: RDY — 80.8% short (0.6M / 0.7M)
Short: 582,399 | Exempt: 0 | TRF Vol: 720,510 | Short Ratio: 80.8% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: RDY — 77.0% short (0.7M / 1.0M)
Short: 740,079 | Exempt: 325 | TRF Vol: 960,684 | Short Ratio: 77.0% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: RDY — 84.9% short (0.9M / 1.0M)
Short: 886,762 | Exempt: 0 | TRF Vol: 1,044,949 | Short Ratio: 84.9% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
FDA
Amiodarone Hydrochloride
WARNING: PULMONARY, HEPATIC and CARDIAC TOXICITY Amiodarone hydrochloride tablets is intended for use only in patients with the indicated life-threate
Mar 17, 2026
FDA
Fluoxetine
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adul
Sep 7, 2022
FDA
VIGABATRIN
Jan 14, 2019
FDA
VIGABATRIN